The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a sharehold ...

The vaccines are intended to be developed for use against Marburg virus and Sudan ebolavirus, two hemorrhagic fevers in the ...

The US Department of Health and Human Services is weighing whether to fund new Marburg and Sudan Ebola virus vaccines even as Secretary Robert F. Kennedy Jr. overhauls the US immunization landscape, ...

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

As Synedgen's Chief Executive Officer and Chief Scientific Officer, Dr. Saward will continue to lead the company to deliver on the successful partnership with Biomedical Advanced Research Agency (BARD ...

The firm is seeking marketing clearance for its Liaison NES real-time PCR instrument along with a multiplex test for flu A/B, COVID-19, and respiratory syncytial virus infection.

Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory review for INTERCEPT RBC is advancing ...